David Kaminetzky MD
Clotting Disorder, Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Clinical Associate Professor, Medicine, New York University School of Medicine
Join to View Full Profile
160 E 34th StNew York, NY 10016
Phone+1 212-731-5452
Fax+1 646-754-9650
Dr. Kaminetzky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- David Kaminetzky, MD, is a hematologist based in New York, NY, specializing in hematologic oncology, clotting disorders, and myeloproliferative disorders. He completed his medical education at Albert Einstein College of Medicine in 2003 and pursued further training with fellowships at Memorial Sloan Kettering Cancer Center and NYU Grossman School of Medicine. He currently serves as a Clinical Associate Professor at NYU Langone Health and an Assistant Professor at New York University School of Medicine. Dr. Kaminetzky is experienced in treating amyloidosis, non-Hodgkin lymphoma, myeloma, leukemia, MDS, and benign hematology. His research has been published in various journals, including Leukemia and Cell Reports, with work on topics like multiple myeloma and Hodgkin's lymphoma. He received CMS Meaningful Use Stage 1 Certification from Epic Systems Corporation in 2012-2013.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Blood & Bone Marrow Transplant, 2010 - 2011
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2007 - 2010
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 2003 - 2007
Albert Einstein College of MedicineClass of 2003
Certifications & Licensure
NY State Medical License 2005 - 2026
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Publications & Presentations
PubMed
- Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.Gaurav Varma, Lindsay Fogel, Beth Gordon, Mateo Mejia Saldarriaga, Jaeil Ahn
Leukemia & Lymphoma. 2025-01-05 - terraFlow, a high-parameter analysis tool, reveals T cell exhaustion and dysfunctional cytokine production in classical Hodgkin's lymphoma.Daniel Freeman, Catherine Diefenbach, Linda Lam, Tri Le, Jason Alexandre
Cell Reports. 2024-08-27 - 6 citationsImmune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders.Raissa Aoun, Daniel Gratch, David Kaminetzky, Ilya Kister
Current Neurology and Neuroscience Reports. 2023-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
